Abstract
Acquired angioedema with low C1-inhibitor (AA) is a rare, serious disease. Primary management options involve treatment of underlying causes and controlling acute episodes. There is no FDA-approved long-term prophylactic therapy for these unpredictable, debilitating, and/or life-threatening attacks of angioedema. Lanadelumab, approved to treat hereditary angioedema, has not been studied in the treatment of AA but offers a logical therapeutic target given similar pathophysiology between the diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
